2025-05-16


Congratulations! The third phase of Qingdao Baheal Pharmaceutical project has officially started operation, taking the high-end formulation production capacity to a new level.

  On May 16, 2025, Qingdao Baheal Pharmaceutical Co., Ltd. (referred to as "Qingdao Baheal Pharmaceutical"), a subsidiary of Baheal Pharmaceutical (301015.SZ), held a relocation ceremony for the Phase III construction project. Leaders and guests including Zhu Xiaowei, Director of Baheal Pharmaceutical Group, Vice President of Baheal Pharmaceutical, and Chairman of Baheal Pharmaceutical; Hao Yu, Vice President of Park Operations of Baheal Pharmaceutical Group; Zheng Aiju, General Manager of Qingdao Baheal Pharmaceutical; as well as colleagues from Qingdao Baheal Pharmaceutical attended the event together to witness this important moment.


Qingdao Baiyang Pharmaceutical

  The completed Phase III project covers a total construction area of over 28,000㎡, including a comprehensive office building, production workshops for tablets, granules, hard capsules, and supporting facilities. With this, the total land area of Qingdao Baheal Pharmaceutical has reached 85,600㎡. After the project officially goes into production, it will add a drug production capacity of 5.6 billion tablets/granules, becoming a key production platform supporting the company's future development and injecting strong momentum into promoting high-quality development.


Director of Baheal Pharmaceutical Group, Vice President of Baheal Pharmaceutical, Chairman of Baheal Pharmaceutical Zhu Xiaowei

  The completion of Phase III has enhanced the company's production capacity and intelligence level, further strengthening the company's core competitiveness. Taking this relocation as a new starting point, we will continue to uphold the philosophy of 'innovation-driven, quality first,' continuously increase R&D investment, improve production processes, provide customers with higher quality products and services, and help more internationally advanced drugs benefit a wide range of patients.

  As a high-end sustained-release formulation R&D and production platform under Baheal Pharmaceutical, Qingdao Baheal Pharmaceutical has long focused on the research, production, and commercialization of dosage forms such as osmotic pumps, microgranule coatings, and skeleton tablets. The company has repeatedly passed the US FDA cGMP certification with "zero defects," with multiple products achieving simultaneous production and marketing in China and the US, demonstrating significant advantages in building international quality standards.

  Among them, the independently developed osmotic pump sustained-release formulation Metformin Nida has filled the domestic gap in this type of controlled-release technology. Patients can achieve stable blood sugar control with once-daily dosing. It has been launched in both China and the US and included in the national medical insurance catalog. In addition, high-end formulations such as Nifedipine Nait and Duloxetine Nashu have also been selected in national centralized procurement, effectively improving clinical drug accessibility and patient medication experience.
  In addition to continuously deepening large-scale production of high-end sustained-release formulations, Qingdao Baiyang Pharmaceutical actively promotes the development and production of innovative drugs. The anti-tuberculosis chemical drug Class 1 new drug NTB-3119M jointly applied with the Institute of Materia Medica, Chinese Academy of Medical Sciences, has entered Phase I clinical trials and is expected to become an innovative treatment drug for drug-resistant tuberculosis independently developed in China, bringing hope to patients with drug-resistant tuberculosis. Furthermore, under the overall strategic guidance of the group, Qingdao Baiyang Pharmaceutical will also build a high-standard, specialized production base for nuclear medicine supporting drug boxes, assisting the transformation and implementation of innovative nuclear medicine cold drug products.
  In the context of biomedicine moving towards new quality productivity, this project relocation not only represents a comprehensive upgrade of Qingdao Baheal Pharmaceutical's production conditions but also provides strong support for the company's future deep cultivation in the high-end formulation field and accelerating the industrialization of innovative achievements. In the future, Baheal Pharmaceutical will continue to uphold the mission of "optimizing medical scenarios through technological innovation," strengthen drug development and process innovation, and continuously contribute to promoting local innovative drugs to the world and serving global patient health.

Related News